The Edge Case Issue: Kisspeptin, GHK-Cu, and Three Compounds Worth Watching in H2 2026

The compounds in Issues 5 through 10 have community consensus behind them. Thousands of operators have run the Wolverine stack. Hundreds of thousands have been on sema or tirz. The GH axis compounds have a two-decade community history, a deep vendor ecosystem, and a literature base you can actually read end to end.

This issue covers different territory. Three compounds: kisspeptin, GHK-Cu, and a forward-intelligence pick. The argument for covering them now: the operators who understand these mechanisms earliest write better protocols later. The argument against: the evidence is thin enough that half the conclusions here may need updating in 12 months.

Both things are true. That is the honest frame going in.

Kisspeptin is a neuropeptide produced primarily in the hypothalamus. It is an endogenous activator of the GnRH pulse generator — the master switch for the HPG axis. GPR54, also called KISS1R, is the kisspeptin receptor. The physiology runs like this: kisspeptin pulses drive GnRH pulses, GnRH pulses drive LH and FSH, LH and FSH drive testosterone and estrogen production downstream. The whole HPG axis runs on that chain.

Kisspeptin neurons also integrate metabolic signals into the reproductive axis. That integration is the mechanism behind what happens when caloric restriction or extreme body fat loss disrupts testosterone and LH in otherwise healthy men and women. The HPG axis is not a closed loop. It reads energy status, and kisspeptin is part of the reading.

That metabolic-reproductive interface is why operators are watching it.

The operator population running GLP-1 compounds for body composition often loses significant weight rapidly. Some report HPG axis disruption downstream: lower testosterone, lower LH, blunted pulse amplitude. The clinical endocrinology literature has documented this in anorexia nervosa and functional hypothalamic amenorrhea for decades. The operator context is different, but the rapid fat mass loss trajectory creates a plausible mechanistic overlap.

The Dhillo group at Imperial College London has published the most directly relevant human kisspeptin data. Their infusion studies in hypogonadal men and in women with functional hypothalamic amenorrhea showed kisspeptin infusion can restore LH and FSH pulsatility in suppressed-axis subjects. That is Tier 1 evidence in a clinically defined population. The mechanism is well-established. The signal is real in that context.

What the literature does not show: oral kisspeptin efficacy (most kisspeptin peptides are short sequences degraded rapidly in the gut), long-term outcomes from sustained supplementation, or validated protocols in the healthy-but-optimizing operator population the Brief covers. Kisspeptin peptides offered in RUO channels are typically the kisspeptin-10 or kisspeptin-54 sequences; both are short peptides that degrade rapidly when not delivered parenterally. Both have the clinical literature behind them for mechanism only. The translation to the non-clinical population is extrapolation.

Applying the Literature Test from Issue 1: Human RCT data? Yes, in clinically hypogonadal and functional hypothalamic amenorrhea subjects. That is Tier 1 in that population. Healthy-operator extrapolation from those trials? Tier 4. Mechanism quality? Tier 1 — the GnRH pulse generator role is textbook endocrinology. The gap is route, dosing, and validated use outside clinical populations.

One COA note, following the framework from Issue 2: kisspeptin is under-studied enough that vendor quality variance matters more, not less. Mass spec confirmation of peptide identity and purity is the minimum standard. On thin-literature compounds, a bad batch is harder to diagnose because the expected response signal is not well-characterized. Do not cut corners on the COA because the compound is obscure.

GHK-Cu is glycine-histidine-lysine, a tripeptide copper complex. It is endogenous — found in human plasma, urine, and saliva — and its plasma concentration declines measurably with age. The foundational biological work came out of Loren Pickart's lab beginning in the 1970s. Pickart identified GHK as a growth factor-activating peptide from plasma, later characterized the copper binding and its role in biological activity, and built out the wound-healing literature over decades. The Pickart corpus is the place to start on GHK-Cu. It is a real lab, real publications, real primary literature.

The modern evidence base covers three axes: skin and wound healing, anti-inflammatory activity, and gene-expression modulation.

On the topical side, the evidence is solid. Multiple small RCTs have shown topical GHK-Cu improves wound healing, dermal thickness, and skin quality markers. The esthetic medicine community has used topical GHK-Cu for years on exactly this basis. Tier 1 to Tier 2 evidence for topical application in wound and skin endpoints. That is not in dispute.

The systemic picture is different. The RUO operator community uses GHK-Cu subcutaneously and intradermally. The human literature for systemic use is thin. Most of the mechanistic data for systemic GHK-Cu is rodent models and cell culture — Tier 3. The extrapolation from topical wound healing endpoints to systemic repair and anti-inflammatory effects in humans is mechanistically plausible. It is not validated by controlled human trials for systemic administration.

The most interesting recent work in the GHK-Cu literature is the gene-regulation angle. Pickart's analysis of transcriptomic datasets suggests GHK-Cu modulates expression across hundreds of genes related to inflammation, collagen synthesis, and neurological function. The gene-expression findings are intriguing and would, if validated in controlled human trials, represent a meaningful mechanism beyond topical wound support. The operative word is if.

The honest read: topical GHK-Cu has a real evidence base. Systemic RUO use in operators is ahead of the literature. The copper complex chemistry matters for COA interpretation — stability and purity of copper coordination in the final compound are non-trivial to verify. Apply Issue 2 COA standards: mass spec identity confirmation and purity certificate are the floor on any GHK-Cu vendor.

Cagrisema is not currently available in RUO channels. This section covers it as forward intelligence, not as a compound you can source today. That distinction is explicit.

Cagrisema is Novo Nordisk's co-formulation of semaglutide with cagrilintide, a long-acting amylin analog. Amylin is a pancreatic hormone co-secreted with insulin at meals. It signals satiety via the area postrema and nucleus tractus solitarius in the brainstem, suppresses post-meal glucagon, and slows gastric emptying. Amylin is a real physiological satiety signal, distinct from GLP-1. Most operators on sema are running a GLP-1 mechanism alone. Cagrisema adds the amylin mechanism on top of it.

The mechanism differentiation matters. Tirzepatide adds GIP co-agonism to GLP-1. Cagrisema adds amylin co-agonism to GLP-1. These are different receptor profiles with different hypothesized downstream effects on body composition, lean mass preservation, and metabolic adaptation. Whether the clinical outcomes diverge meaningfully is what the Phase 3 REDEFINE trial program is designed to answer.

The REDEFINE 1 Phase 3 readout is the most-watched data drop in the GLP-1 space in H2 2026. Phase 2 data suggested approximately 25% weight loss at 68 weeks — above semaglutide alone in matched timelines. If REDEFINE 1 confirms that efficacy delta, cagrisema becomes the successor-question for every operator currently on sema. The Brief is covering the mechanism now so you understand the receptor biology before the news cycle requires a fast read.

When the data hits, coverage will assume you do not know what amylin does. You now do.

Three signal-watches for the next six months.

REDEFINE 1 Phase 3 readout. Cagrisema vs. semaglutide, body weight primary endpoint. If the efficacy delta holds at scale, it reshapes the stack conversation immediately. Expected H2 2026.

Kisspeptin in the rapid-weight-loss population. Watch endocrinology journals for case reports or small series documenting HPG axis suppression in GLP-1 users, and any kisspeptin-adjacent intervention data. The intersection of rapid fat mass reduction and HPG function is an emerging operator-relevant question. The literature is not there yet. It will be.

GHK-Cu systemic bioavailability. If any human pharmacokinetic data publishes for subcutaneous GHK-Cu, it would be the first controlled bioavailability anchor for the RUO community. Current dosing is entirely extrapolated from in vitro and rodent work. Human PK data would change that.

The edge compounds are where the arc is heading, not where it has been.

Kisspeptin is mechanistically rich and clinically thin for the healthy operator. The GnRH pulse generator role is established. The RUO translation is extrapolation. Understand the mechanism. Watch the literature.

GHK-Cu has a real topical evidence base and a more speculative systemic one. Pickart's work is foundational and worth reading primary. The gene-regulation angle is the most interesting current frontier. COA discipline is not optional.

Cagrisema is forward intelligence. Amylin plus GLP-1 is a distinct mechanism from GIP plus GLP-1. Know the difference before the REDEFINE 1 news cycle requires you to have a view.

The Literature Test from Issue 1 still applies to every compound in every issue, including this one. Especially this one.

Issue 12 — The Compound at 12: The stack I am actually running into Q3, and what is next for this briefing. The arc closes. The sequel arc opens.

Colby

For research use only. Not medical advice. Compounds discussed are sold for research purposes; nothing here is a recommendation to use them on humans or animals. The publisher of The Compound has a financial interest in heroxbio.com, an RUO peptide vendor; this relationship may influence which compounds are covered. See the About page for full disclosure.